New cancer drug YL211 enters first human tests

NCT ID NCT06384352

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are to check safety and see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

YL211 (an antibody-drug conjugate given intravenously)

What this could lead to

If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.

What could go wrong

This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and it will take years before any potential treatment is confirmed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer gastric adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma hepatocellular carcinoma intrahepatic bile duct cancer neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China-Japan Friendship Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100029, China

    Contact

  • Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley

    RECRUITING

    Las Vegas, Nevada, 89169, United States

    Contact

  • Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office

    RECRUITING

    Sarasota, Florida, 34232-6422, United States

    Contact Email: •••••@•••••

    Contact

  • Gosford Hospital

    RECRUITING

    Gosford, New South Wales, 2250, Australia

    Contact

  • Monash Health

    RECRUITING

    Melbourne, Australia

    Contact Email: •••••@•••••

    Contact

  • NEXT Oncology - Dallas

    RECRUITING

    Irving, Texas, 75039, United States

    Contact Email: •••••@•••••

    Contact

  • NEXT Oncology - Houston

    RECRUITING

    Houston, Texas, 77055, United States

    Contact

  • NEXT San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Email: •••••@•••••

  • One Clinical Research - Nedlands

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

    Contact

  • Princess Margaret Hospital

    RECRUITING

    Toronto, Toronto, Canada

    Contact Email: •••••@•••••

    Contact

  • Sarah Cannon Research Institute (SCRI) at HealthONE

    RECRUITING

    Denver, Colorado, 80218-1238, United States

    Contact Email: •••••@•••••

    Contact

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    RECRUITING

    Orlando, Florida, 32827, United States

    Contact

    Contact Email: •••••@•••••

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, China

    Contact Email: •••••@•••••

    Contact

    Contact

  • The First Affiliated Hospital - Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact

  • The Ottawa Hospital - General Campus

    RECRUITING

    Ottawa, Canada

    Contact Email: •••••@•••••

    Contact

  • The University of Texas - MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • University of Cincinnati Vontz Center for Molecular Studies

    RECRUITING

    Cincinnati, Ohio, 45219, United States

    Contact

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

    Contact Email: •••••@•••••

  • Wenzhou Medical University - The First Affiliated Hospital

    RECRUITING

    Wenzhou, Zhejiang, 325000, China

    Contact

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, China

    Contact Email: •••••@•••••

    Contact

  • Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven

    RECRUITING

    North Haven, Connecticut, 06473-2142, United States

    Contact Email: •••••@•••••

    Contact